BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2302455)

  • 1. Monoclonal antibody T-cell-depleted HLA-haploidentical bone marrow transplantation for Wiskott-Aldrich syndrome.
    Rumelhart SL; Trigg ME; Horowitz SD; Hong R
    Blood; 1990 Feb; 75(4):1031-5. PubMed ID: 2302455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report.
    Fischer A; Friedrich W; Fasth A; Blanche S; Le Deist F; Girault D; Veber F; Vossen J; Lopez M; Griscelli C
    Blood; 1991 Jan; 77(2):249-56. PubMed ID: 1985691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
    Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
    Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center.
    Ozsahin H; Le Deist F; Benkerrou M; Cavazzana-Calvo M; Gomez L; Griscelli C; Blanche S; Fischer A
    J Pediatr; 1996 Aug; 129(2):238-44. PubMed ID: 8765621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement.
    Moen RC; Horowitz SD; Sondel PM; Borcherding WR; Trigg ME; Billing R; Hong R
    Blood; 1987 Sep; 70(3):664-9. PubMed ID: 3304460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unrelated donor BMT for Wiskott-Aldrich syndrome.
    Lenarsky C; Weinberg K; Kohn DB; Parkman R
    Bone Marrow Transplant; 1993 Aug; 12(2):145-7. PubMed ID: 8401361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome.
    Brochstein JA; Gillio AP; Ruggiero M; Kernan NA; Emanuel D; Laver J; Small T; O'Reilly RJ
    J Pediatr; 1991 Dec; 119(6):907-12. PubMed ID: 1960605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies.
    Filipovich AH; Shapiro RS; Ramsay NK; Kim T; Blazar B; Kersey J; McGlave P
    Blood; 1992 Jul; 80(1):270-6. PubMed ID: 1611094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.
    Filipovich AH; Stone JV; Tomany SC; Ireland M; Kollman C; Pelz CJ; Casper JT; Cowan MJ; Edwards JR; Fasth A; Gale RP; Junker A; Kamani NR; Loechelt BJ; Pietryga DW; Ringdén O; Vowels M; Hegland J; Williams AV; Klein JP; Sobocinski KA; Rowlings PA; Horowitz MM
    Blood; 2001 Mar; 97(6):1598-603. PubMed ID: 11238097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.
    van Rood JJ; Loberiza FR; Zhang MJ; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
    Blood; 2002 Mar; 99(5):1572-7. PubMed ID: 11861270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
    Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
    Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haploidentical bone marrow transplantation in a pediatric patient with Wiskott-Aldrich syndrome. A case report.
    Pury S; López Orozco M; Pichichero G; Sasia LV; Morell D; Álvarez MS; Basquiera AL; Mas ME; Salvucci K
    Arch Argent Pediatr; 2024 Feb; 122(1):e202310061. PubMed ID: 37471507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful unmanipulated haploidentical bone marrow transplantation from an HLA 2-locus-mismatched mother for Wiskott-Aldrich syndrome after unrelated cord blood stem cell transplantation.
    Inagaki J; Park YD; Kishimoto T; Yoshioka A
    J Pediatr Hematol Oncol; 2005 Apr; 27(4):229-31. PubMed ID: 15838398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
    Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
    J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.